- Home
- BLRX vs SYRS Comparison
BLRX vs SYRS Comparison
Compare BLRX & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- SYRS
- Stock Information
- Founded
- BLRX 2003
- SYRS 2011
- Country
- BLRX Israel
- SYRS United States
- Employees
- BLRX N/A
- SYRS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- SYRS Health Care
- Exchange
- BLRX Nasdaq
- SYRS Nasdaq
- Market Cap
- BLRX 36.0M
- SYRS 7.1M
- IPO Year
- BLRX 2011
- SYRS 2016
- Fundamental
- Price
- BLRX $0.20
- SYRS $0.22
- Analyst Decision
- BLRX Strong Buy
- SYRS Hold
- Analyst Count
- BLRX 2
- SYRS 5
- Target Price
- BLRX $5.50
- SYRS $3.00
- AVG Volume (30 Days)
- BLRX 1.7M
- SYRS 2.6M
- Earning Date
- BLRX 11-25-2024
- SYRS 10-31-2024
- Dividend Yield
- BLRX N/A
- SYRS N/A
- EPS Growth
- BLRX N/A
- SYRS N/A
- EPS
- BLRX N/A
- SYRS N/A
- Revenue
- BLRX $21,991,000.00
- SYRS $386,000.00
- Revenue This Year
- BLRX N/A
- SYRS N/A
- Revenue Next Year
- BLRX N/A
- SYRS $1,011.11
- P/E Ratio
- BLRX N/A
- SYRS N/A
- Revenue Growth
- BLRX N/A
- SYRS N/A
- 52 Week Low
- BLRX $0.19
- SYRS $0.18
- 52 Week High
- BLRX $1.68
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- BLRX 25.94
- SYRS 29.17
- Support Level
- BLRX $0.23
- SYRS $0.19
- Resistance Level
- BLRX $0.56
- SYRS $0.21
- Average True Range (ATR)
- BLRX 0.03
- SYRS 0.02
- MACD
- BLRX 0.00
- SYRS 0.07
- Stochastic Oscillator
- BLRX 11.82
- SYRS 20.53
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.